Paper39366135
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development.
Corvaja C and 6 others. Cancer Treat Rev, 2024. Cited by 69 papers, by iCite.
Cite this record
ConductScience Library. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development. Papers, record 39366135. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39366135
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| ErbB Receptors | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Mutation | Major topic |
| Humans | |
| Aniline Compounds | |
| Acrylamides | |
| Drug Resistance, Neoplasm | |
| Antineoplastic Agents | |
| Indoles | |
| Pyrimidines |
Source PubMed
Cited by56
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42964587 | Overcoming adaptive resistance in non-small cell lung cancer: integrating targeted therapies, immunotherapy synergy, and nanocarrier delivery. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42964587 | PubMed |
| 42919317 | ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42919317 | PubMed |
| 42917883 | A Structural Perspective on Non-covalent Targeting of Conserved Polar Residues in Protein Kinases. | J Med Chem | 2026 | https://conductscience.org/library/papers/42917883 | PubMed |
| 42891869 | Effectiveness of local ablative therapy combined with first-line tyrosine kinase inhibitors in epidermal growth factor receptor-mutated oligometastatic non-small cell lung cancer: a systematic review and meta-analysis. | Clin Exp Metastasis | 2026 | https://conductscience.org/library/papers/42891869 | PubMed |
| 42827960 | Oral mucositis risk with EGFR tyrosine kinase inhibitor monotherapies and combination regimens in non-small cell lung cancer: a systematic review and network meta-analysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42827960 | PubMed |
| 42757482 | A four‑gene signature identifies TKI‑induced persister cells and uncovers a ZLN005‑induced pyroptotic vulnerability via the GSDME pathway in EGFR‑mutant lung cancer. | Mol Med Rep | 2026 | https://conductscience.org/library/papers/42757482 | PubMed |
| 42729980 | Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation? | Cancer Drug Resist | 2026 | https://conductscience.org/library/papers/42729980 | PubMed |
| 42639301 | Immune checkpoint inhibitor-based combinatory and alternative strategies for immune treatment of lung cancers. | Front Immunol | 2026 | https://conductscience.org/library/papers/42639301 | PubMed |
| 42588669 | Targeting EGFR Endocytosis and Signaling for Cancer Drug Delivery and Cancer Treatment. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588669 | PubMed |
| 42536589 | Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study. | Medicine (Baltimore) | 2026 | https://conductscience.org/library/papers/42536589 | PubMed |
| 42519174 | ColdstartMHDTI: integrating biomolecular pretraining and attention-based heterogeneous graph learning for drug-target interaction prediction. | Front Chem | 2026 | https://conductscience.org/library/papers/42519174 | PubMed |
| 42463770 | Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants. | Oncogene | 2026 | https://conductscience.org/library/papers/42463770 | PubMed |
| 42440354 | Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42440354 | PubMed |
| 42436136 | Specimen quality shapes the actionable genomic landscape in comprehensive cancer genomic profiling. | NPJ Genom Med | 2026 | https://conductscience.org/library/papers/42436136 | PubMed |
| 42334959 | Recent progress in cancer multidrug resistance and therapeutic options associated with protein damage response. | Protein Cell | 2026 | https://conductscience.org/library/papers/42334959 | PubMed |
| 42260055 | Pigmentary Changes Reported with Tyrosine Kinase Inhibitors: A Narrative Review of Mechanisms and Clinical Implications. | Clin Drug Investig | 2026 | https://conductscience.org/library/papers/42260055 | PubMed |
| 42179048 | Design and Pictet-Spengler enabled synthesis of carboxamide-substituted imidazo[1,2-a]quinoxalines as dual EGFR and tubulin targeting anticancer agents. | J Enzyme Inhib Med Chem | 2026 | https://conductscience.org/library/papers/42179048 | PubMed |
| 42106797 | CASK promotes non-small cell lung cancer growth through coordinated regulation of EGFR expression, trafficking, and p21 expression. | J Biomed Sci | 2026 | https://conductscience.org/library/papers/42106797 | PubMed |
| 42102692 | 4-Anilinoquinazoline carbamate derivatization as a platform for prodrug design and localized drug delivery. | Bioorg Chem | 2026 | https://conductscience.org/library/papers/42102692 | PubMed |
| 41976235 | Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies. | Molecules | 2026 | https://conductscience.org/library/papers/41976235 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| SLTM | 79811 | PubTator's text mining | https://conductscience.org/library/genes/79811 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39366135
GET https://conductscience.org/api/papers/v1/39366135/cited_by?page=2